JosephKashMD

Oncology • Naperville, IL

Breast Cancer, Hematologic Oncology

Edward Cancer Center

Join to view full profile

Dr. Kash is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kash's full profile

Already have an account?

Office
801 S Washington St
Naperville, IL 60540
Phone+1 630-527-3000

Fax+1 630-527-3505

Education & Training

Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Loyola University Medical CenterResidency, Internal Medicine, 1993 - 1996
University of Illinois College of MedicineClass of 1993

Certifications & Licensure

IL State Medical License 1995 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Alpha Omega Alpha 1992

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

353 citations
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guid...
Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Michael A. Bookman, William A. Cliby
Gynecologic Oncology. 2016-10-01
107 citations
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guid...
Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Michael A. Bookman, William A. Cliby
Journal of Clinical Oncology. 2016-09-27
256 citations
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
Shelly S. Lo, Patricia B. Mumby, John Norton, Karen Rychlik, Jeffrey B. Smerage
Journal of Clinical Oncology. 2010-04-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Member
American Society of Hematology - ASH
Member